Gilead Sciences, Inc. $GILD Shares Sold by Securian Asset Management Inc.

Securian Asset Management Inc. lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 1.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 65,007 shares of the biopharmaceutical company’s stock after selling 941 shares during the period. Securian Asset Management Inc.’s holdings in Gilead Sciences were worth $7,207,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Brighton Jones LLC lifted its stake in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 2,450 shares during the period. Bison Wealth LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter worth $215,000. GAMMA Investing LLC lifted its stake in shares of Gilead Sciences by 24.9% in the 1st quarter. GAMMA Investing LLC now owns 22,760 shares of the biopharmaceutical company’s stock worth $2,550,000 after acquiring an additional 4,532 shares during the period. Nilsine Partners LLC acquired a new stake in shares of Gilead Sciences in the 1st quarter worth $208,000. Finally, Cambridge Investment Research Advisors Inc. lifted its stake in shares of Gilead Sciences by 25.3% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 190,773 shares of the biopharmaceutical company’s stock worth $21,376,000 after acquiring an additional 38,530 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of several recent analyst reports. BMO Capital Markets raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a research note on Monday. Cantor Fitzgerald raised their price objective on shares of Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Citigroup raised their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Wednesday, October 8th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective for the company in a research note on Tuesday, August 19th. Finally, Needham & Company LLC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a research note on Friday, July 25th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $121.14.

Check Out Our Latest Stock Analysis on Gilead Sciences

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the completion of the transaction, the chief executive officer directly owned 595,725 shares in the company, valued at approximately $67,692,231.75. This trade represents a 1.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the sale, the chief financial officer owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 71,500 shares of company stock worth $8,281,540. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $123.11 on Tuesday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The firm has a 50-day moving average price of $115.27 and a two-hundred day moving average price of $110.62. Gilead Sciences, Inc. has a twelve month low of $85.60 and a twelve month high of $124.11. The company has a market capitalization of $152.76 billion, a P/E ratio of 24.52, a price-to-earnings-growth ratio of 0.84 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILDGet Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same period last year, the firm posted $2.01 EPS. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Read More

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.